JUL 18, 2021 3:34 PM PDT

COVID-19 Antibiotic No More Effective than Placebo

WRITTEN BY: Annie Lennon

Azithromycin, a broad-spectrum antibiotic commonly used to prevent symptoms of COVID-19 in non-hospitalized patients, does not prevent COVID-19 symptoms from arising and may even increase a person's chance of hospitalization. The corresponding study was published in JAMA by researchers in California. 

Azithromycin is widely prescribed in the US and the rest of the world as a treatment for COVID-19. It was initially recommended on the basis that its anti-inflammatory properties may help prevent the progression of COVID-19 if used early on in the disease. 

"Most of the trials done so far with azithromycin have focused on hospitalized patients with pretty severe disease," said Catherine Oldenburg, lead author of the study. "Our paper is one of the first placebo-controlled studies showing no role for azithromycin in outpatients."

For the study, researchers recruited 263 people who tested positive for SARS-CoV-2 within seven days of enrolment. None of the patients were hospitalized at the beginning of the study. 

They were split into two treatment groups: the first group of 171 participants received a single, 1.2 gram oral dose of azithromycin, while the second group of 92 participants received an identical placebo. 

By day 14, the researchers found that there was no significant difference in the proportion of participants in either group who were symptom-free. In both groups, 50% of participants had no symptoms. By day 21, while patients given the antibiotic had been hospitalized, the same was true for none of the participants in the placebo group. 

The researchers conclude that their findings do not support the routine use of azithromycin for outpatients SARS-CoV-2 infection as the drug seemingly performs no better than a placebo in preventing COVID-19 symptoms from arising, as well as hospitalization from the disease. 

 

Sources: JAMAEurekAlert

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
MAY 02, 2021
Cannabis Sciences
Medical Cannabis for Epilepsy May Be Linked to Early Puberty
MAY 02, 2021
Medical Cannabis for Epilepsy May Be Linked to Early Puberty
Current research suggests that cannabidiol (CBD) oil may be effective in managing seizures in childhood-onset epilepsy. ...
MAY 14, 2021
Health & Medicine
A National Standard THC Dose for Researchers is Here
MAY 14, 2021
A National Standard THC Dose for Researchers is Here
    Whatever your stance on cannabis, almost  everyone would agree that more, better quality, research sh ...
MAY 22, 2021
Drug Discovery & Development
Drug Combo Treats 86% of Patients with Gout
MAY 22, 2021
Drug Combo Treats 86% of Patients with Gout
Researchers at the University of Michigan have found that a combination of two drugs is twice as effective as current tr ...
JUN 10, 2021
Plants & Animals
Antibiotics Fight Mysterious Coral Disease
JUN 10, 2021
Antibiotics Fight Mysterious Coral Disease
Coral reefs besieged by climate change and pollutants have a new line of defense against disease-an antibiotic commonly ...
JUN 18, 2021
Drug Discovery & Development
FDA Approves First New Drug Since 2014 for Weight-loss
JUN 18, 2021
FDA Approves First New Drug Since 2014 for Weight-loss
A new medication called ‘Wegovy’ produced by Novo Nordisk has been approved by the Food and Drug Administrat ...
JUL 15, 2021
Drug Discovery & Development
The genomics of high blood pressure - a road to the future of treatment
JUL 15, 2021
The genomics of high blood pressure - a road to the future of treatment
The human heart begins to beat in utero in the early weeks of development and continues throughout life. In an average l ...
Loading Comments...